Abrocitinib treatment in adolescents and adults with moderate-to-severe atopic dermatitis: Early pruritus responses from phase 3 trials jade mono-1 and jade mono-2
ISAD > Events > ISAD 2020 (live) > ISAD 2020 (live) programme > Abrocitinib treatment in adolescents and adults with moderate-to-severe atopic dermatitis: Early pruritus responses from phase 3 trials jade mono-1 and jade mono-2
This content is password protected. To view it please enter your password below:
TRACKING INFO
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
